EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Drug Product Development of Lipid Nanoparticle‐Based mRNA Therapeutics and Vaccines

Gideon Kersten, Eleonora Cerasoli, Bruce Kerwin, Olivia M Merkel iD, Andrea Hawe iD

WIREs Nanomedicine and Nanobiotechnology · 2026

DOI: 10.1002/wnan.70053 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift WIREs Nanomedicine and Nanobiotechnology, 2026. Verfasst von Gideon Kersten und 4 weiteren Autor:innen. Beteiligte Einrichtung: Coriolis Pharma Research GmbH, Martinsried, Germany. Hauptthemen laut MEDLINE: Nanoparticles, Lipids, Vaccines, RNA, Messenger. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 271 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lipid nanoparticles (LNP) are currently the most relevant non‐viral delivery systems for mRNA and occasionally for smaller nucleic acids such as small interfering RNA. Although the manufacturing of LNP is well established and scalable equipment is available for production, LNP drug product development is not straightforward. Numerous factors influence product quality, including LNP composition, process parameters, and formulation composition. A proper understanding and control of the critical variables is essential for product development of LNP containing pharmaceuticals. This article provides an overview on the drug product development roadmap for LNP‐based therapeutics and vaccines. Based on the quality target product profile and current scientific and technical knowledge, key aspects that may impact product quality will be discussed. Strategies to identify failure risks as early in the development process as possible and ways to mitigate them will be addressed. The majority of steps in the development are covered, including LNP design and LNP manufacturing process, analytical development, and formulation development to achieve a stable and safe product suitable for human application. This article is categorized under: Biology‐Inspired Nanomaterials > Lipid‐Based Structures

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesLipidsVaccinesRNA, MessengerDrug DevelopmentHumansAnimalsLiposomes

Stichwörter der Autor:innen

drug product developmentlipid nanoparticlesmRNAnanomedicinespharmaceutical development

Substanzen

LipidsVaccinesRNA, MessengerLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Coriolis Pharma Research GmbH, Martinsried, Germany.
  • Leiden Academic Center for Drug Research, Leiden University, Leiden, the Netherlands.
  • Kerwin Biopharma Consulting LLC, Bainbridge Island, Washington, USA.
  • Department of Pharmacy, Ludwig Maximilians University, Munich, Germany.

ORCID-Profile: Olivia M Merkel, Andrea Hawe

Zitieren

APA

Kersten, G., Cerasoli, E., Kerwin, B., Merkel, O. M., & Hawe, A. (2026). Drug Product Development of Lipid Nanoparticle‐Based mRNA Therapeutics and Vaccines. WIREs Nanomedicine and Nanobiotechnology. https://doi.org/10.1002/wnan.70053

Vancouver

Kersten G, Cerasoli E, Kerwin B, Merkel OM, Hawe A. Drug Product Development of Lipid Nanoparticle‐Based mRNA Therapeutics and Vaccines. WIREs Nanomedicine and Nanobiotechnology. 2026. doi:10.1002/wnan.70053

BibTeX
@article{Kersten2026,
  author = {Kersten, Gideon and Cerasoli, Eleonora and Kerwin, Bruce and Merkel, Olivia M and Hawe, Andrea},
  title = {Drug Product Development of Lipid Nanoparticle‐Based mRNA Therapeutics and Vaccines},
  journal = {WIREs Nanomedicine and Nanobiotechnology},
  year = {2026},
  doi = {10.1002/wnan.70053}
}
Kostenlos starten →